Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 148

1.

Immune response to sipuleucel-T in prostate cancer.

Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, Quinn DI.

Cancers (Basel). 2012 Apr 18;4(2):420-41. doi: 10.3390/cancers4020420.

PMID:
24213318
[PubMed]
Free PMC Article
2.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
[PubMed - indexed for MEDLINE]
3.

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.

Sims RB.

Vaccine. 2012 Jun 19;30(29):4394-7. doi: 10.1016/j.vaccine.2011.11.058. Epub 2011 Nov 26. Review.

PMID:
22122856
[PubMed - indexed for MEDLINE]
Free Article
4.

Sipuleucel-T: immunotherapy for advanced prostate cancer.

Olson BM, McNeel DG.

Open Access J Urol. 2011 May 3;3:49-60. doi: 10.2147/OAJU.S13069. Review.

PMID:
24198636
[PubMed]
Free PMC Article
5.

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.

Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.

Cancer Control. 2013 Jan;20(1):7-16. Review.

PMID:
23302902
[PubMed - indexed for MEDLINE]
Free Article
6.

Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.

Thara E, Dorff TB, Pinski JK, Quinn DI.

Maturitas. 2011 Aug;69(4):296-303. doi: 10.1016/j.maturitas.2011.04.012. Epub 2011 May 31. Review.

PMID:
21621934
[PubMed - indexed for MEDLINE]
7.

Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.

Gardner TA, Elzey BD, Hahn NM.

Hum Vaccin Immunother. 2012 Apr;8(4):534-9. doi: 10.4161/hv.19795. Review.

PMID:
22832254
[PubMed - indexed for MEDLINE]
8.

Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists.

Garcia JA.

Ther Adv Med Oncol. 2011 Mar;3(2):101-8. doi: 10.1177/1758834010397692.

PMID:
21789160
[PubMed]
Free PMC Article
9.

The evolving role of immunotherapy in prostate cancer.

Gerritsen WR.

Ann Oncol. 2012 Sep;23 Suppl 8:viii22-7. doi: 10.1093/annonc/mds259. Review.

PMID:
22918924
[PubMed - indexed for MEDLINE]
Free Article
10.

Beyond sipuleucel-T: immune approaches to treating prostate cancer.

Cheng ML, Fong L.

Curr Treat Options Oncol. 2014 Mar;15(1):115-26. doi: 10.1007/s11864-013-0267-z. Review.

PMID:
24402184
[PubMed - indexed for MEDLINE]
11.

Cancer immunotherapy: sipuleucel-T and beyond.

Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P.

Pharmacotherapy. 2011 Aug;31(8):813-28. doi: 10.1592/phco.31.8.813. Review.

PMID:
21923608
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.

Gomella LG, Gelpi-Hammerschmidt F, Kundavram C.

Can J Urol. 2014 Apr;21(2 Supp 1):48-56.

PMID:
24775724
[PubMed - in process]
Free Article
13.

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlovi─ç S.

Prostate. 2004 Aug 1;60(3):197-204.

PMID:
15176049
[PubMed - indexed for MEDLINE]
14.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Di Lorenzo G, Ferro M, Buonerba C.

BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16. Review.

PMID:
22177289
[PubMed - indexed for MEDLINE]
15.

Sipuleucel-T and immunotherapy in the treatment of prostate cancer.

Dawson NA, Roesch EE.

Expert Opin Biol Ther. 2014 May;14(5):709-19. doi: 10.1517/14712598.2014.896897. Epub 2014 Mar 12.

PMID:
24620782
[PubMed - indexed for MEDLINE]
16.

Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.

Garcia JA, Dreicer R.

Oncology (Williston Park). 2011 Mar;25(3):242-9.

PMID:
21548467
[PubMed - indexed for MEDLINE]
Free Article
17.

Current vaccination strategies for prostate cancer.

Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.

Eur Urol. 2012 Feb;61(2):290-306. doi: 10.1016/j.eururo.2011.09.020. Epub 2011 Oct 3. Review.

PMID:
22001436
[PubMed - indexed for MEDLINE]
18.

Advances in prostate cancer immunotherapies.

Basler M, Groettrup M.

Drugs Aging. 2007;24(3):197-221. Review.

PMID:
17362049
[PubMed - indexed for MEDLINE]
19.

The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.

Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.

Eur Urol. 2012 Apr;61(4):639-47. doi: 10.1016/j.eururo.2011.10.027. Epub 2011 Oct 24. Review.

PMID:
22036643
[PubMed - indexed for MEDLINE]
20.

Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.

Graff JN, Drake CG, Beer TM.

Urology. 2013 Feb;81(2):381-3. doi: 10.1016/j.urology.2012.10.044.

PMID:
23374810
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk